REPROCELL join Medicines Discovery Catapult’s Virtual R&D network to accelerate drug development
12 March 2019
REPROCELL has joined Medicines Discovery Catapult’s Virtual R&D platform – a unique national network of consultants, private sector CROs, expert labs and public sector centres of excellence, providing medicines discovery expertise, services and virtual programme management.
ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production
10 October 2018
Learn more about the partnership between REPROCELL and ROSLINCT aiming to improve efficiency of induced pluripotent stem cell production
REPROCELL’s Dr David Bunton on April 2018 Trade Mission to China with Scottish First Minister Nicola Sturgeon
18 April 2018
REPROCELL Europe’s CEO, Dr David Bunton, was part of the trade mission to China undertaken by the Scottish First Minister, the Rt. Hon. Nicola Sturgeon MSP, 9-13 April 2018.
Derek Mackay, SNP Cabinet Secretary for Finance and the Constitution, visits REPROCELL Europe, Glasgow
06 April 2018
Read about REPROCELL's visit from Derek Mackay, the Scottish National Party’s Cabinet Secretary for Finance and the Constitution, on 05 April 2017
REPROCELL’s David Bunton addresses the Scottish Parliament
21 March 2018
Discussing how sectors, such as life science, are affected by Scotland’s economic performance and what actions are required to make the economy more inclusive, innovative and international. Topics include key factors in company success, SME’s and government partnership.
Patient-derived tumor organoids recapitulate clinical treatments
14 March 2018
REPROCELL is currently working to develop a highly predictive three-dimensional (3D) human micro-intestine model that can be used to test new drugs for the treatment of IBD and gastrointestinal cancers.
REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services
08 November 2017
PALO ALTO, CA, November 8, 2017 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research services and procurement of human biospecimens, announced today that REPROCELL has selected the Science Exchange platform.
Article by Dr David Bunton (co-authored) in the European Pharmaceutical Review, Autumn 2017
27 September 2017
REPROCELL Europe Ltd’s CEO, Dr David Bunton, has co-authored an article titled New Strategy that has been published in the European Pharmaceutical Review, Autumn 2017.
Nicola Sturgeon: interview at the official opening of REPROCELL’s Centre for Predictive Drug Discovery (YouTube video)
10 August 2017
Video: First Minister Nicola Sturgeon officially opened the new European headquarters of a life sciences company which is set to generate 15 new jobs and safeguard a further three following new investment.
Press Release: Nicola Sturgeon, First Minister of Scotland, opens REPROCELL European Headquarters in Glasgow
10 August 2017
REPROCELL Europe Ltd (REPROCELL), a leading provider of products and services for research in stem cells, drug discovery, human tissues and 3D cell culture and a member of the REPROCELL Group, has opened its European headquarters in Glasgow, UK.
REPROCELL Europe’s CEO Dr David Bunton presented at NC3Rs workshop: Human tissue models for cancer research
03 March 2017
REPROCELL Europe’s CEO, Dr David Bunton presented at the recent NC3Rs meeting on the use of human tissues in cancer research. The conference considered the potential for human tissue models to help reduce clinical drug attrition and provide more relevant models of cancer
REPROCELL Inc CEO meets with Scottish Cabinet Secretary Fiona Hyslop in Japan
14 February 2017
Read about the REPROCELL CEO's meeting with Fiona Hyslop, Cabinet Secretary for Culture, Tourism and External Affairs for the Scottish Government
Scottish Enterprise Association Honours REPROCELL with Annual Awards Nomination
07 February 2017
Read about REPROCELL CEO Dr David Bunton's nomination for the Scottish Enterprise Association Life Science Business Leadership Award
Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy
11 November 2016
Read about REPROCELL's partnership with Steminent Biotherapeutics to develop and commercialize Steminent’s allogeneic stem cell therapy product Stemchymal.
Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins
13 May 2016
Proteon Therapeutics Announces Publication in Cardiovascular Pharmacology: Open Access Describing Promising Nonclinical Results for Vonapanitase in Improving Arteriovenous Fistula (AVF) Maturation and patency in Chronic Kidney Disease (CKD) Patients.
Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase
21 April 2016
Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease.
REPROCELL acquires Biopta to expand its drug discovery services
25 November 2015
The Japanese regenerative medicine company REPROCELL Inc. has announced the acquisition of the Scottish life sciences company, Biopta.
Biopta co-authors research in the European Respiratory Journal
18 November 2015
The impact of fresh human tissue studies for translational work performed at Biopta has once again been demonstrated with this latest publication at the European Respiratory Society.
REPROCELL announces publication of a research report on “3D Skin Model Construction,” submitted to the International Scientific Journal “Molecular Cancer Therapeutics” by REPROCELL and others
19 October 2015
Read more about REPROCELL CSO Professor Stefan Przyborski's latest publication on 3D Skin Model Construction published in Molecular Cancer Therapeutics
New paper demonstrates formation of spontaneously active neuronal networks by stem cell derived neurons in 3D Alvetex Scaffold culture system
05 March 2015
A recently published paper by Imogen Smith et al. demonstrates the use of the Alvetex platform to culture 3D differentiated human neural stem cells.